Ken Griffin Kronos Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.5 $20,332 - $33,150	-22,100 Reduced 70.38%	9,300 $9,000
Q2 2024 Aug 14, 2024	BUY	$0.73 - $1.38 $19,418 - $36,708	26,600 Added 554.17%	31,400 $38,000
Q1 2024 May 15, 2024	BUY	$1.02 - $1.3 $4,896 - $6,240	4,800 New	4,800 $6,000
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $13,534 - $26,462	10,100 Added 2525.0%	10,500 $15,000
Q4 2022 Feb 14, 2023	BUY	$1.44 - $3.44 $576 - $1,376	400 New	400 $0

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $51.1M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.